» Articles » PMID: 32351329

Role of Cancer Stem Cells in the Development of Giant Cell Tumor of Bone

Overview
Journal Cancer Cell Int
Publisher Biomed Central
Date 2020 May 1
PMID 32351329
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

The primary bone tumor is usually observed in adolescence age group which has been shown to be part of nearly 20% of the sarcomas known today. Giant cell tumor of bone (GCTB) can be benign as well as malignant tumor which exhibits localized dynamism and is usually associated with the end point of a long bone. Giant cell tumor (GCT) involves mononuclear stromal cells which proliferate at a high rate, multinucleated giant cells and stromal cells are equally present in this type of tumor. Cancer stem cells (CSCs) have been confirmed to play a potential role in the development of GCT. Cancer stem cell-based microRNAs have been shown to contribute to a greater extent in giant cell tumor of bone. CSCs and microRNAs present in the tumors specifically are a great concern today which need in-depth knowledge as well as advanced techniques to treat the bone cancer effectively. In this review, we attempted to summarize the role played by cancer stem cells involving certain important molecules/factors such as; Mesenchymal Stem Cells (MSCs), miRNAs and signaling mechanism such as; mTOR/PI3K-AKT, towards the formation of giant cell tumor of bone, in order to get an insight regarding various effective strategies and research advancements to obtain adequate knowledge related to CSCs which may help to focus on highly effective treatment procedures for bone tumors.

Citing Articles

Single-cell RNA sequencing reveals differential expression of EGFL7 and VEGF in giant-cell tumor of bone and osteosarcoma.

Feleke M, Feng W, Song D, Li H, Rothzerg E, Wei Q Exp Biol Med (Maywood). 2022; 247(14):1214-1227.

PMID: 35695550 PMC: 9379604. DOI: 10.1177/15353702221088238.


The prognosis of giant cell tumor of bone and the vital risk factors that affect its postoperative recurrence: a meta-analysis.

Lin X, Liu J, Xu M Transl Cancer Res. 2022; 10(4):1712-1722.

PMID: 35116496 PMC: 8799031. DOI: 10.21037/tcr-20-3100.


Footprints of microRNAs in Cancer Biology.

Rajasegaran Y, Azlan A, Rosli A, Yik M, Kang Zi K, Mohd Yusoff N Biomedicines. 2021; 9(10).

PMID: 34680611 PMC: 8533183. DOI: 10.3390/biomedicines9101494.


Cell Biology of Giant Cell Tumour of Bone: Crosstalk between m/wt Nucleosome H3.3, Telomeres and Osteoclastogenesis.

Forsyth R, Krenacs T, Athanasou N, Hogendoorn P Cancers (Basel). 2021; 13(20).

PMID: 34680268 PMC: 8534144. DOI: 10.3390/cancers13205119.


Targeting Oncoimmune Drivers of Cancer Metastasis.

Kudo-Saito C, Ozaki Y, Imazeki H, Hayashi H, Masuda J, Ozawa H Cancers (Basel). 2021; 13(3).

PMID: 33535613 PMC: 7867187. DOI: 10.3390/cancers13030554.


References
1.
Kim W, Ryu C . Cancer stem cell surface markers on normal stem cells. BMB Rep. 2017; 50(6):285-298. PMC: 5498139. DOI: 10.5483/bmbrep.2017.50.6.039. View

2.
Yuan H, Wang T, Zhang K . MicroRNAs as potential biomarkers for diagnosis, therapy and prognosis of gastric cancer. Onco Targets Ther. 2018; 11:3891-3900. PMC: 6039071. DOI: 10.2147/OTT.S156921. View

3.
Klein M, Siegal G . Osteosarcoma: anatomic and histologic variants. Am J Clin Pathol. 2006; 125(4):555-81. DOI: 10.1309/UC6K-QHLD-9LV2-KENN. View

4.
Allen-Rhoades W, Whittle S, Rainusso N . Pediatric Solid Tumors in Children and Adolescents: An Overview. Pediatr Rev. 2018; 39(9):444-453. DOI: 10.1542/pir.2017-0268. View

5.
Vaishya R, Agarwal A, Vijay V . 'Salvage Treatment' of Aggressive Giant Cell Tumor of Bones with Denosumab. Cureus. 2015; 7(7):e291. PMC: 4524749. DOI: 10.7759/cureus.291. View